<DOC>
	<DOCNO>NCT00714116</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) SBI-087 subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE ( great equal 4 American College Rheumatology [ ACR ] Revised Criteria ) great 6 month study day 1 . History positive antinuclear antibody ( ANA ) titer great equal 1:160 equivalent . Treatment 20 mg prednisone per day . Evidence unstable clinically significant disease ( e.g. , cardiovascular , cerebrovascular , respiratory , renal disease , unstable serious disorder ) SLE . History cancer ( resect cutaneous basal squamous cell carcinoma situ cervical cancer ) less 5 year ' documentation diseasefree state .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>